Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4458367

Brc1ccc(Oc2ccc(-c3c[nH]c(COc4ccccc4)n3)cc2)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 7/20 0.48
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
FFAR1 O14842 3/20 0.39
FFAR4 Q5NUL3 3/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
PPARG P37231 1/20 0.38
PPARD Q03181 1/20 0.38
PPARA Q07869 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
XDH P47989 1/20 0.37
SCN4A P35499 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4460353 0.95 MCL1 (0.47) MCL1FFAR1FFAR4HDAC1HDAC2
SCHEMBL4680696 0.90 MCL1 (0.48) MCL1NPC1RAB9AKMT2AKDM4E
Trifluoroacetic Acid SCHEMBL8216241 0.85 HDAC3 (0.40) MCL1NPC1RAB9AKMT2AHDAC1
SCHEMBL4686964 0.84 MCL1 (0.46) MCL1NPC1RAB9AKMT2ATDP1
Trifluoroacetic Acid SCHEMBL4470387 0.84 PPARG (0.41) MCL1RAB9AKMT2ALMNAPPARG
SCHEMBL4684167 0.82 MCL1 (0.50) MCL1KDM4E
Trifluoroacetic Acid SCHEMBL3270278 0.82 MTNR1B (0.45) MCL1NPC1RAB9AHDAC1HDAC2
SCHEMBL4460360 0.82 LTA4H (0.47) MCL1NPC1RAB9AKMT2ALMNA
SCHEMBL4460374 0.81 MCL1 (0.45) MCL1NPC1RAB9AKMT2AKDM4E
SCHEMBL4460188 0.81 NPC1 (0.45) MCL1NPC1RAB9AKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7534805-B2 Imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-05-19 US claimed
EP-1638943-B1 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT SOD CONSEILS RECH APPLIC (FR) 2008-08-06 EP claimed
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-03-22 US claimed
US-7534805-B2 Imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-05-19 US disclosed
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments MIF, MCL1, PPIP5K2 MCL1 2/4885NPC1 512/4885RAB9A 2552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.